Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Grigory Khimulya
AddedMar 31, 2024
UpdatedMay 31, 2026
Grigory Khimulya

Grigory Khimulya

Co-Founder & CEO, Telis Bioscience

CrunchbaseLinkedIn

Grigory Khimulya's Career

Telis Bioscience
Telis Bioscience

Cambridge, MA, US

Co-Founder & CEO· C-Suite · Management
Zeta Surgical
Zeta Surgical

Boston, MA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Grigory Khimulya's Career

Telis Bioscience
Telis Bioscience
Pre-Seed$1M62019Cambridge, MA, US
Co-Founder & CEO· C-Suite · Management

Leadership at Telis Bioscience

Kyle FishKyle FishCo-Founder

Similar to Telis Bioscience

AI ProteinsAI ProteinsBoston, MA, USProtein Therapeuticsest. 2021AI ProteinsBoston, MA, US · est. 2021

AI Proteins: A biotech firm specializing in the design and engineering of synthetic mini protein therapeutics.

Series B · $18.2M44
BigHat BiosciencesBigHat BiosciencesSan Mateo, CA, USTherapeuticsest. 2019BigHat BiosciencesSan Mateo, CA, US · est. 2019

BigHat: Leveraging AI to engineer advanced protein therapeutics for complex diseases.

Series B · $99.3M92
Protillion BiosciencesProtillion BiosciencesBurlingame, CA, USProtein Librariesest. 2019Protillion BiosciencesBurlingame, CA, US · est. 2019

Protillion Biosciences: Revolutionizing therapeutic antibody discovery with our high-tech protein display platform.

Series A · $18M9
Nabla BioNabla BioBoston, MA, USAntibody Designest. 2020Nabla BioBoston, MA, US · est. 2020

AI-driven design of therapeutic antibodies for complex diseases.

Seed · $11.4M9
Zeta Surgical
Zeta Surgical
Seed$8.8M102018Boston, MA, US
Co-Founder

Leadership at Zeta Surgical

Jose AmichJose AmichFounder
Raahil ShaRaahil ShaFounder

Similar to Zeta Surgical

Revolve SurgicalRevolve SurgicalToronto, Ontario, CASurgical Robotsest. 2019Revolve SurgicalToronto, Ontario, CA · est. 2019

Revolve: Affordable, compact surgical robotics for all operating rooms.

Pre-Seed · $125k7
Illuminant SurgicalIlluminant SurgicalCambridge, MA, USSurgical Navigationest. 2021Illuminant SurgicalCambridge, MA, US · est. 2021

Illuminant: Enhancing surgery with skin-projected x-rays and real-time navigation.

Pre-Seed · $500k4
XSurgical RoboticsXSurgical RoboticsCambridge, MA, USSurgical Instruments, Surgical Robotsest. 2009XSurgical RoboticsCambridge, MA, US · est. 2009

XSurgical: Innovating surgical practice with advanced robotic instruments and technology.

Angel · $54.8k30
AiM Medical RoboticsAiM Medical RoboticsWorcester, MA, USMedical Devicesest. 2018AiM Medical RoboticsWorcester, MA, US · est. 2018

AiM Medical Robotics: Innovating neurosurgery with precise, efficient, portable MRI-functional robots.

Series A · $3.4M30

Grigory Khimulya's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailBrian KimBrian KimCo-Founder · KakaoKim Beom-sooKim Beom-sooCo-Founder · Kakao

People Similar to Grigory Khimulya

Dmitry KuzminDmitry KuzminCo-Founder · 4Bio CapitalGregory AsmolovGregory AsmolovCo-Founder · PitchMeJohn KlockJohn KlockCo-Founder · BioMarinErich HuangErich HuangFounder · ClineticKyle MichelKyle MichelCo-Founder · Citrine InformaticsValeriya GritsenkoValeriya GritsenkoCo-Founder · Neurowired